Constipation drug lubiprostone protects kidney function in chronic kidney disease

sciencedaily.com

A constipation drug, lubiprostone, has demonstrated a significant ability to protect kidney function in a clinical trial. The drug slowed the decline of kidney function in individuals with moderate chronic kidney disease (CKD) compared to a placebo, by boosting spermidine production and improving gut bacteria and mitochondrial activity. Researchers plan a larger Phase 3 trial, aiming for personalized CKD treatments that focus on gut health and mitochondrial function, potentially offering a new therapeutic avenue.


With a significance score of 4.9, this news ranks in the top 2% of today's 28852 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


Constipation drug lubiprostone protects kidney function in chronic kidney disease | News Minimalist